Morgan Stanley Reiterates Underweight on Genmab, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has reiterated an 'Underweight' rating on Genmab (NASDAQ:GMAB) and maintained a $33 price target.
July 17, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has reiterated an 'Underweight' rating on Genmab, maintaining a $33 price target.
The 'Underweight' rating from Morgan Stanley suggests that they expect Genmab's stock to underperform compared to other stocks in the market. This could potentially lead to a decrease in the stock's price in the short term. The maintained price target of $33 also indicates that the analyst does not foresee significant growth in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100